邮件订阅 RSS

留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展

谷涛,  于经瀛

downloadPDF
文章导航 > 协和医学杂志  > 2021 >  12(3): 380-385
谷涛, 于经瀛. 肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展[J]. 协和医学杂志, 2021, 12(3): 380-385. doi: 10.3969/j.issn.1674-9081.2020.00.012
引用本文: 谷涛, 于经瀛. 肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展[J]. 协和医学杂志, 2021, 12(3): 380-385. doi: 10.3969/j.issn.1674-9081.2020.00.012
shu
GU Tao, YU Jingying. New Progress in the Treatment of Advanced Primary Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 380-385. doi: 10.3969/j.issn.1674-9081.2020.00.012
Citation: GU Tao, YU Jingying. New Progress in the Treatment of Advanced Primary Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(3): 380-385. doi: 10.3969/j.issn.1674-9081.2020.00.012
shu

肝动脉化疗栓塞术治疗原发性进展性肝细胞癌新进展

doi: 10.3969/j.issn.1674-9081.2020.00.012

  • 国家老年医学中心 中国医学科学院老年医学研究所 北京医院放射科，北京100730

详细信息
    通讯作者:

    于经瀛 电话：010-85133818, E-mail: yjingying@sohu.com

  • 中图分类号: R735.7; R730.53

New Progress in the Treatment of Advanced Primary Hepatocellular Carcinoma with Transcatheter Arterial Chemoembolization

  • Department of Radiology, Beijing Hospital, Institute of Geriatric Medicine, Chinese Academy of Medical Sciences, National Center of Gerontology, Beijing 100730, China

More Information

    摘要
  • 摘要: 肝细胞癌(hepatocellular carcinoma, HCC)是我国最常见的恶性肿瘤之一。在治疗不可切除HCC方面，肝动脉化疗栓塞术(transcatheter arterial chemoembolization，TACE)是目前应用最广泛的局部治疗方式。随着技术的发展，TACE治疗的安全性和有效性不断提高，适应证范围亦逐步扩大。本文主要综述TACE治疗原发性进展性HCC的最新技术及未来发展方向，以期为临床决策提供指导。
    Abstract: Hepatocellular carcinoma(HCC) is one of the most common malignant tumors in China. Transcatheter arterial chemoembolization(TACE) is currently the most widely used locoregional treatment for unresectable HCC. With the development of technology, TACE has improved in the safety and efficacy and expanded the scope of treatment indications. The aim of this article is to summarize the latest technology and future development of TACE including TACE with drug-eluting beads in the treatment of advanced primary HCC, in order to provide guidance for clinical decision-making.
    作者贡献: 谷涛负责收集并整理文献资料；谷涛、于经瀛负责撰写并修改论文。
    利益冲突: 无
    • HTML全文
    • 参考文献(48)
  • [1] Cao MM, Li H, Sun DQ, et al. Cancer burden of major cancers in China: A need for sustainable actions[J]. Cancer Commun(Lond), 2020, 40: 205-210. doi:  10.1002/cac2.12025
    [2] 中华预防医学会肿瘤预防与控制专业委员会感染相关肿瘤防控学组, 中华预防医学会慢病预防与控制分会, 中华预防医学会健康传播分会. 中国肝癌一级预防专家共识(2018)[J]. 中华肿瘤杂志, 2018, 40: 550-557. doi:  10.3760/cma.j.issn.0253-3766.2018.07.013

    Prevention of Infection Related Cancer(PIRCA) Group, Specialized Committee of Cancer Prevention and Control, Chinese Preventive Medicine Association; Non-communi-cable & Chronic Disease Control and Prevention Society, Chinese Preventive Medicine Association; Health Communication Society, Chinese Preventive Medicine Association. Strategies of Primary Prevention of Liver Cancer in China: Expert Consensus(2018)[J]. Zhonghua Zhong Liu Za Zhi, 2018, 40: 550-557. doi:  10.3760/cma.j.issn.0253-3766.2018.07.013
    [3] Wang MJ, Wang YT, Feng MS, et al. Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center[J]. Int J Infect Dis, 2017, 65: 15-21. doi:  10.1016/j.ijid.2017.09.003
    [4] 夏宇, 姜玉新, 戴晴, 等. 肝细胞肝癌超声造影增强模式对分化程度的诊断价值[J]. 协和医学杂志, 2014, 5: 46-49. doi:  10.3969/j.issn.1674-9081.2014.01.011

    Xia Y, Jiang YX, Dai Q, et al. Contrast-enhanced Ultrasound of Hepatocellular Carcinoma: Enhancement Pattern Features for Evaluation of Tumor Differentiation[J]. Xie He Yi Xue Za Zhi, 2014, 5: 46-49. doi:  10.3969/j.issn.1674-9081.2014.01.011
    [5] 左婷婷, 郑荣寿, 曾红梅, 等. 中国肝癌发病状况与趋势分析[J]. 中华肿瘤杂志, 2015, 37: 691-696. doi:  10.3760/cma.j.issn.0253-3766.2015.09.013

    Zuo TT, Zheng RS, Zeng HM, et al. Analysis of Liver Cancer Incidence and Trend in China[J]. Zhonghua Zhong Liu Za Zhi, 2015, 37: 691-696. doi:  10.3760/cma.j.issn.0253-3766.2015.09.013
    [6] 中华医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J]. 中华放射学杂志, 2019, 53: 246-255. doi:  10.3760/cma.j.issn.1005-1201.2019.04.003

    Chinese College of Interventionalists, Chinese Medical Doctor Association. Chinese Clinical Practice Guidelines for Transarterial Chemoembolization of Hepatocellular Carcinoma[J]. Zhonghua Fang She Xue Za Zhi, 2019, 53: 246-255. doi:  10.3760/cma.j.issn.1005-1201.2019.04.003
    [7] 中华医师协会介入医师分会. 中国肝细胞癌经动脉化疗栓塞治疗临床实践指南[J]. 中华介入放射学电子杂志, 2019, 7: 178-184. doi:  10.3877/cma.j.issn.2095-5782.2019.03.002

    Chinese College of Interventionalists, Chinese Medical Doctor Association. Chinese Clinical Practice Guidelines for Transarterial Chemoembolization of Hepatocellular Carcinoma[J]. Zhonghua Jie Ru Fang She Xue Za Zhi, 2019, 7: 178-184. doi:  10.3877/cma.j.issn.2095-5782.2019.03.002
    [8] Hartke J, Johnson M, Ghabril M. The diagnosis and treatment of hepatocellular carcinoma[J]. Semin Diagn Pathol, 2017, 34: 153-159. doi:  10.1053/j.semdp.2016.12.011
    [9] European Association For The Study Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56: 908-943. doi:  10.1016/j.jhep.2011.12.001
    [10] Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update[J]. Hepatology, 2011, 53: 1020-1022. doi:  10.1002/hep.24199
    [11] Varela M, Real MI, Burrel M, et al. Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics[J]. J Hepatol, 2007, 46: 474-481. doi:  10.1016/j.jhep.2006.10.020
    [12] Lammer J, Malagari K, Vogl T, et al. Prospective rando-mized study of doxorubicin-eluting-beads embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study[J]. Cardiovasc Intervent Radiol, 2010, 33: 41-52. doi:  10.1007/s00270-009-9711-7
    [13] Burrel M, Reig M, Forner A, et al. Survival of patients with hepatocellular carcinoma treated by transarterial chemoembolization(TACE) using drug eluting beads: Implications for clinical practice and trial design[J]. J Hepatol, 2012, 56: 1330-1335. doi:  10.1016/j.jhep.2012.01.008
    [14] Malagari K, Pomoni M, Sotirchos VS, et al. Long term recurrence analysis post drug eluting bead(deb) chemoembolization for hepatocellular carcinoma(HCC)[J]. Hepatogastroenterology, 2013, 60: 1413-1419. http://europepmc.org/abstract/MED/23933933
    [15] Wen P, Chen SD, Wang JR, et al. Comparison of treatment response and survival profiles between drug-eluting bead transarterial chemoembolization and conventional transarterial chemoembolization in Chinese hepatocellular carcinoma patients: a prospective cohort study[J]. Oncol Res, 2019, 27: 583-592. doi:  10.3727/096504018X15368325811545
    [16] Li H, Wu FC, Duan M, et al. Drug-eluting bead transar- terial chemoembolization(TACE)vs conventional TACE in treating hepatocellular carcinoma patients with multiple conventional TACE treatments history: A comparison of efficacy and safety[J]. Medicine(Baltimore), 2019, 98: e15314.
    [17] Xiao YD, Ma C, Zhang ZS, et al. Safety and efficacy assessment of transarterial chemoembolization using drug-eluting beads in patients with hepatocellular carcinoma and arterioportal shunt: a single-center experience[J]. Cancer Manag Res, 2019, 11: 1551-1557. doi:  10.2147/CMAR.S193948
    [18] Ou MC, Liu YS, Chuang MT, et al. Time-to-progression following conventional compared with drug-eluting-bead transcatheter arterial chemoembolization in patients with large hepatocellular carcinoma[J]. Clin Radiol, 2019, 74: 295-300. doi:  10.1016/j.crad.2018.12.008
    [19] Kim HC. Radioembolization for the treatment of hepato-cellular carcinoma[J]. Clin Mol Hepatol, 2017, 23: 109-114. doi:  10.3350/cmh.2017.0004
    [20] Saini A, Wallace A, Alzubaidi S, et al. History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma[J]. J Clin Med, 2019, 8: 55. doi:  10.3390/jcm8010055
    [21] Lobo L, Yakoub D, Picado O, et al. Unresectable hepatocellular carcinoma: Radioembolization Versus Chemoembolization: A Systematic Review and Meta-analysis[J]. Cardiovasc Intervent Radiol, 2016, 39: 1580-1588. doi:  10.1007/s00270-016-1426-y
    [22] Llovet JM, Real MI, Montana X, et al. Arterial embolization or chemoembolization versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomized controlled trial[J]. Lancet, 2002, 359: 1734-1739. doi:  10.1016/S0140-6736(02)08649-X
    [23] Kis B, El-Haddad G, Sheth RA, et al. Liver-Directed Therapies for Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma[J]. Cancer Control, 2017, 24: 1073274817729244. http://europepmc.org/abstract/MED/28975829
    [24] Herren JL, Disomma N, Ray CE Jr. Hepatocellular Carcinoma: Combined Transarterial Chemoembolization and Ablation[J]. Semin Intervent Radiol, 2019, 36: 279-284. doi:  10.1055/s-0039-1694066
    [25] 孙玉, 张洪海, 生守鹏, 等. 经肝动脉化疗栓塞术联合射频消融治疗巴塞罗那B期原发性肝癌的效果及预后影响因素分析[J]. 临床肝胆病杂志, 2019, 35: 818-824. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD201904029.htm

    Sun Y, Zhang HH, Sheng SP, et al. Clinical Effect of Transcatheter Arterial Chemoembolization Combined with Radiofrequency Ablation in Treatment of Barcelona Clinical Liver Cancer Stage B Primary Liver Cancer and Influencing Factors for Prognosis[J]. Lin Chuang Gan Dan Bing Za Zhi, 2019, 35: 818-824. https://www.cnki.com.cn/Article/CJFDTOTAL-LCGD201904029.htm
    [26] 杨海明, 孙世蒙, 于海东, 等. TACE联合氩氦刀冷冻治疗中晚期原发性肝癌的安全性和疗效分析[J]. 实用放射学杂志, 2019, 35: 444-447.

    Yang HM, Sun SM, Yu HD, et al. The Safety and Curative Effect of TACE Combined with Argon Helium Knife Cryoablation in the Treatment of Advanced Primary Hepatic Cancer[J]. Shi Yong Fang She Xue Za Zhi, 2019, 35: 444-447.
    [27] 马顺茂, 刘红磊, 刘永红, 等. 肝动脉化疗栓塞联合无水酒精消融术治疗原发性肝癌的疗效及安全性分析[J]. 肝胆外科杂志, 2019, 27: 47-50. https://www.cnki.com.cn/Article/CJFDTOTAL-GDWZ201901012.htm

    Ma SM, Liu HL, Liu YH, et al. Efficacy and Safety of TACE Combined with Percutaneous Ethanol Injection for Primary Liver Cancer[J]. Gan Dan Wai Ke Za Zhi, 2019, 27: 47-50. https://www.cnki.com.cn/Article/CJFDTOTAL-GDWZ201901012.htm
    [28] Li X, Feng GS, Zheng CS, et al. Expression of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma and effect of transcatheter arterial chemoembolization therapy on plasma vascular endothelial growth factor level[J]. World J Gastroenterol, 2004, 10: 2878-2882. doi:  10.3748/wjg.v10.i19.2878
    [29] Wang B, Xu H, Gao ZQ, et al. Increased expression of vascular endothelial growth factor in hepatocellular carcinoma after transcatheter arterial chemoembolization[J]. Acta Radiol, 2008, 49: 523-529. doi:  10.1080/02841850801958890
    [30] 管清龙, 纪卫政, 任伟新, 等. 肝癌介入治疗后血清缺氧诱导因子和血管内皮生长因子含量变化对预后的影响[J]. 介入放射学杂志, 2014, 23: 142-146. doi:  10.3969/j.issn.1008-794X.2014.02.014

    Guan QL, Ji WZ, Ren WX, et al. The Influence of Serum HIF-1α and VEGF Content on the Prognosis in Patients with Hepatocellular Carcinoma after TACE[J]. Jie Ru Fang She Xue Za Zhi, 2014, 23: 142-146. doi:  10.3969/j.issn.1008-794X.2014.02.014
    [31] 贾中芝, 黄渊全, 冯耀良, 等. 原发性肝癌TACE前后血清HIF-1α、VEGF与CT灌注成像的相关性分析[J]. 中华医学杂志, 2013, 93: 1472-1475. doi:  10.3760/cma.j.issn.0376-2491.2013.19.009

    Jia ZZ, Huang YQ, Feng YL, et al. Correlations between Serum Hypoxia Inducible Factor-1α, Vascular Endothelial Growth Factor and Computed Tomography Perfusion Imaging at Pre-and Post-TACE in Patients with Primary Hepatic Carcinoma[J]. Zhonghua Yi Xue Za Zhi, 2013, 93: 1472-1475. doi:  10.3760/cma.j.issn.0376-2491.2013.19.009
    [32] Hsieh MY, Lin ZY, Chuang WL. Serial serum VEGF-A, angiopoietin-2, and endostatin measurements in cirrhotic patients with hepatocellular carcinoma treated by transcatheter arterial chemoembolization[J]. Kaohsiung J Med Sci, 2011, 27: 314-322. doi:  10.1016/j.kjms.2011.03.008
    [33] Zhu Y, Feng B, Mei L, et al. Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma[J]. J BUON, 2019, 24: 608-614. http://www.ncbi.nlm.nih.gov/pubmed/31128013
    [34] Li L, Zhao WZ, Wang MM, et al. Transarterial chemoembolization plus sorafenib for the management of unresectable hepatocellular carcinoma: a systematic review and meta-analysis[J]. BMC Gastroenterol, 2018, 18: 138. doi:  10.1186/s12876-018-0849-0
    [35] 马婧嶔, 颜志平. 肝癌介入治疗进一步思考[J]. 介入放射学杂志, 2019, 28: 507-510. doi:  10.3969/j.issn.1008-794X.2019.06.001

    Ma JQ, Yan ZP. Further Consideration on Interventional Therapy of Liver Cancer[J]. Jie Ru Fang She Xue Za Zhi, 2019, 28: 507-510. doi:  10.3969/j.issn.1008-794X.2019.06.001
    [36] Miyayama S, Matsui O. Superselective Conventional Transarterial Chemoembolization for Hepatocellular Carcinoma: Rationale, Technique and Outcome[J]. J Vasc Interv Radiol, 2016, 27: 1269-1278. doi:  10.1016/j.jvir.2016.04.014
    [37] 李智, 倪才方. 经导管肝动脉化疗栓塞术的技术细节与进展[J]. 中华介入放射学电子杂志, 2018, 6: 127-132. doi:  10.3877/cma.j.issn.2095-5782.2018.02.008

    Li Z, Ni CF. Technical Details and Progress of Trans-catheter Hepatic Arterial Chemoembolization[J]. Zhonghua Jie Ru Fang She Xue Dian Zi Za Zhi, 2018, 6: 127-132. doi:  10.3877/cma.j.issn.2095-5782.2018.02.008
    [38] 余晨曦, 滕皋军. 经导管动脉化疗栓塞术抵抗研究进展[J]. 介入放射学杂志, 2017, 26: 1063-1067. doi:  10.3969/j.issn.1008-794X.2017.12.001

    Yu CX, Teng GJ. Transarterial Chemoembolization Refractory: Current Research Progress[J]. Jie Ru Fang She Xue Za Zhi, 2017, 26: 1063-1067. doi:  10.3969/j.issn.1008-794X.2017.12.001
    [39] Sung PS, Yang K, Bae SH, et al. Reduction of Intrahe-patic Tumour by Hepatic Arterial Infusion Chemotherapy Prolongs Survival in Hepatocellular Carcinoma[J]. Anticancer Res, 2019, 39: 3909-3916. doi:  10.21873/anticanres.13542
    [40] Zhuang BW, Li W, Xie XH, et al. Sorafenib versus hepatic arterial infusion chemotherapy for advance hepatocellular carcinoma: a systematic review and meta-analysis[J]. Jpn J Clin Oncol, 2019, 49: 845-855. doi:  10.1093/jjco/hyz069
    [41] Moriya K, Namisaki T, Sato S, et al. Efficacy of bi-monthly hepatic arterial infusion chemotherapy for advanced hepatocellular carcinoma[J]. J Gastrointest Oncol, 2018, 9: 741-749. doi:  10.21037/jgo.2018.05.13
    [42] Lyu N, Kong YN, Mu LW, et al. Hepatic arterial infusion of oxaliplatin plus fluorouracil/leucovorin vs. sorafenib for advanced hepatocellular carcinoma[J]. J Hepatol, 2018, 69: 60-69. doi:  10.1016/j.jhep.2018.02.008
    [43] Kim HY, Kim JD, Bae SH, et al. A comparative study of high-dose hepatic arterial infusion chemotherapy and transarterial chemoembolization using doxorubicin for intractable, advanced hepatocellular carcinoma[J]. Korean J Hepatol, 2010, 16: 355-361. doi:  10.3350/kjhep.2010.16.4.355
    [44] Moriya K, Namisaki T, Sato S, et al. Bi-monthly hepatic arterial infusion chemotherapy as a novel strategy for advanced hepatocellular carcinoma in decompensated cirrhotic patients[J]. Clin Mol Hepatol, 2019, 25: 381-389. doi:  10.3350/cmh.2019.0037
    [45] 赵明. 精准医疗时代背景下的肝动脉灌注化疗[J]. 中山大学学报(医学科学版), 2019, 40: 648-656. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201905002.htm

    Zhao M. Hepatic Arterial Infusion Chemotherapy in the Era of Precise Medicine[J]. Zhongshan Da Xue Xue Bao(Yi Xue Ke Xue Ban), 2019, 40: 648-656. https://www.cnki.com.cn/Article/CJFDTOTAL-ZSYK201905002.htm
    [46] Silva JP, Berger NG, Tsai S, et al. Transarterial chemoembolization in hepatocellular carcinoma with portal vein tumor thrombosis: a systematic review and meta-analysis[J]. HPB(Oxford), 2017, 19: 659-666.
    [47] Xie H, Tian ST, Cui L, et al. Adjuvant trans-arterial chemoembolization after hepatectomy significantly improves the prognosis of low-risk patients with R0-stage hepatocellular carcinoma[J]. Cancer Manag Res, 2019, 11: 4065-4073. doi:  10.2147/CMAR.S195485
    [48] Peng J, Kang S, Ning ZY, et al. Residual convolutional neural network for predicting response of transarterial chemoembolization in hepatocellular carcinoma from CT imaging[J]. Eur Radiol, 2020, 30: 413-424. doi:  10.1007/s00330-019-06318-1
    • 相关文章
    • 施引文献
  • 资源附件(0)
  • 加载中
WeChat 点击查看大图
计量
  • 文章访问数:  278
  • HTML全文浏览量:  39
  • PDF下载量:  30
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-10-09
  • 录用日期:  2020-02-27
  • 网络出版日期:  2020-08-11
  • 刊出日期:  2021-05-30

目录

    /

    返回文章
    返回
    友情链接: 国家卫生健康委员会 北京协和医院 中国医学科学院 学术不端检测系统 国际知识资源总库 中国知网 术语在线 中国全科医学
    地址：北京市东城区帅府园1号 北京协和医院老楼7号楼
    3层302室 《协和医学杂志》编辑部
    电话：010-69154261/4262
    E - mail：medj@pumch.cn
    mjpumch@126.com
    期刊网站版权所有：《协和医学杂志》编辑部
    京ICP备 11002662

    本系统由 北京仁和汇智信息技术有限公司 开发    百度统计

    x 关闭 永久关闭

    【温馨提醒】近日，《协和医学杂志》编辑部接到作者反映，有多名不法人员冒充期刊编辑发送见刊通知，鼓动作者添加微信，从而骗取版面费的行为。特提醒您，本刊与作者联系的方式均为邮件通知或电话，稿件进度通知邮箱为：mjpumch@126.com，编辑部电话为：010-69154261，请提高警惕，谨防上当受骗！如有任何疑问，请致电编辑部核实。谢谢！